Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Nov 21, 2014; 20(43): 15955-15964
Published online Nov 21, 2014. doi: 10.3748/wjg.v20.i43.15955
Published online Nov 21, 2014. doi: 10.3748/wjg.v20.i43.15955
Histopathology of hepatocellular carcinoma
Manuel Schlageter, Luigi Maria Terracciano, Department of Pathology, University Hospital Basel, 4031 Basel, Switzerland
Salvatore D’Angelo, Paolo Sorrentino, Liver Unit, Clinical and Experimental Hepatology, S.G. Moscati General Hospital, 83100 Avellino, Italy
Author contributions: Schlageter M conceived and wrote the article; Terracciano LM conceived and wrote the article; D’Angelo S conceived and supervised the article; Sorrentino P conceived and supervised the article.
Correspondence to: Paolo Sorrentino, MD, PhD, Liver Unit, Clinical and Experimental Hepatology, S.G. Moscati General Hospital, Via Otranto 2, 83100 Avellino, Italy. paolosorrmed@tin.it
Telephone: +39-347-5888993
Received: January 17, 2014
Revised: May 9, 2014
Accepted: July 22, 2014
Published online: November 21, 2014
Revised: May 9, 2014
Accepted: July 22, 2014
Published online: November 21, 2014
Core Tip
Core tip: Hepatocellular carcinoma (HCC) is currently the sixth most common type of cancer with a high mortality rate and an increasing incidence worldwide. HCC most commonly occurs on ground of a cirrhotic liver but interestingly an increasing proportion of HCCs develop in the non-fibrotic or minimal fibrotic. Although this process is yet to be completely understood, this changing scenario also has impact on the material seen by pathologists, presenting them with new diagnostic dilemmas. This review summarizes recent developments and tries to put new HCC biomarkers in context with the WHOs reclassification.